Literature DB >> 10362127

Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression.

M P Wong1, N Cheung, S T Yuen, S Y Leung, L P Chung.   

Abstract

Angiogenesis is an essential requirement for the development, progression and metastasis of malignant tumours. Studies on transgenic mouse models have shown that angiogenesis begins in the pre-malignant phase of oncogenesis, when dysplastic lesions acquire an increased microvasculature. To investigate the relationship between the expression of vascular endothelial growth factor (VEGF) and colorectal tumour progression, we have studied VEGF expression level and splice variant pattern by semi-quantitative RT-PCR and the cellular source of VEGF expression by in situ hybrization (ISH) in a range of lesions that modelled the tumour-development pathway from normal colon to invasive colorectal adenocarcinomas. Colonic adenomas showed a statistically significant up-regulation of VEGF expression over normal tissues, with a further increase during the development of adenocarcinomas. Tumour cells formed the major source of VEGF expression, with a minor contribution from mononuclear cells in the tumour stroma and enhanced expression in tumour cells around necrotic regions. The comparable expression level in both the in situ and invasive components in the same tumours indicated that a high VEGF expression capacity had been acquired prior to establishment of the invasive phenotype. Our findings support activation of VEGF as the molecular basis for the discrete induction of angiogenesis in the pre-malignant phase of colorectal tumour development.

Entities:  

Mesh:

Year:  1999        PMID: 10362127     DOI: 10.1002/(sici)1097-0215(19990611)81:6<845::aid-ijc1>3.0.co;2-5

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  32 in total

1.  Minimally invasive colon resection is associated with a persistent increase in plasma PlGF levels following cancer resection.

Authors:  H M C Shantha Kumara; Jenny C Cabot; Xiaohong Yan; Sonali A C Herath; Martin Luchtefeld; Matthew F Kalady; Daniel L Feingold; Raymond Baxter; Richard L Whelan
Journal:  Surg Endosc       Date:  2010-12-24       Impact factor: 4.584

Review 2.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

3.  Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.

Authors:  Bénédicte F Jordan; Matthew Runquist; Natarajan Raghunand; Amanda Baker; Ryan Williams; Lynn Kirkpatrick; Garth Powis; Robert J Gillies
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

4.  Transgenic expression of VEGF in intestinal epithelium drives mesenchymal cell interactions and epithelial neoplasia.

Authors:  Amelie Boquoi; Rodrigo Jover; Tina Chen; Marieke Pennings; Greg H Enders
Journal:  Gastroenterology       Date:  2008-11-01       Impact factor: 22.682

5.  Antitumor activity of an adenovirus harboring human IL-24 in colon cancer.

Authors:  Shujian Chang; Jicheng Yang; Weichang Chen; Yufeng Xie; Weihua Sheng
Journal:  Mol Biol Rep       Date:  2010-03-31       Impact factor: 2.316

6.  In vitro antimetastatic effect of Changweiqing through antiinvasion of hypoxic colorectal carcinoma LoVo cells.

Authors:  Jing Li; Zhong-Ze Fan; Jue Sun; Jian-Hua Xu
Journal:  Chin J Integr Med       Date:  2011-07-03       Impact factor: 1.978

7.  VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression.

Authors:  M L George; M G Tutton; F Janssen; A Arnaout; A M Abulafi; S A Eccles; R I Swift
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

8.  Predictive value of Smac, VEGF and Ki-67 in rectal cancer treated with neoadjuvant therapy.

Authors:  Hongjiang Yan; Renben Wang; Jinming Yu; Shumei Jiang; Kunli Zhu; Dianbin Mu; Zhongfa Xu
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

9.  Circadian disruption, Per3, and human cytokine secretion.

Authors:  Jaclyn Guess; James B Burch; Kisito Ogoussan; Cheryl A Armstead; Hongmei Zhang; Sara Wagner; James R Hebert; Patricia Wood; Shawn D Youngstedt; Lorne J Hofseth; Udai P Singh; Dawen Xie; William J M Hrushesky
Journal:  Integr Cancer Ther       Date:  2009-11-18       Impact factor: 3.279

10.  Plasma soluble receptor for advanced glycation end-products and risk of colorectal adenoma.

Authors:  Li Jiao; Liang Chen; Abeer Alsarraj; David Ramsey; Zhigang Duan; Hashem B El-Serag
Journal:  Int J Mol Epidemiol Genet       Date:  2012-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.